Uricase and other novel agents for the management of patients with treatment-failure gout.

Successful management of chronic gout depends on reducing body pools of urate. The benchmark of success is to maintain serum urate levels at less than 6 mg/dL using therapies such as probenecid or allopurinol. In a subset of patients with gout, these medications fail to achieve this benchmark, resulting in ongoing signs and symptoms characteristic of treatment-failure gout. Potential therapies now in clinical development show promise for treating this refractory patient population. In this article, we review the clinical characteristics associated with treatment-failure gout and discuss recent data from clinical trials of febuxostat and uricase.

Duke Scholars

Author Michael Steven Hershfield Medicine, Rheumatology and Immunology

Author John Sargent Sundy Medicine, Rheumatology and Immunology